Effectiveness of the MSC Cold Cap System in the Prevention of Chemotherapy-Induced Alopecia

Klouvas, George; Efstathiou, E.; Zervakis, Dimitrios; Papazachariou, E.; Plyta, Marina; Skarlos, D.

doi:10.1159/000048253

Cited by 31 publications

(22 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The manufacturers of these devices were unable to satisfy the FDA's request and, ultimately, these systems failed due to lack of data. However, newer scalp cooling methods that provide more uniform and controlled cooling are undergoing evaluation in Europe with substantial benefit reported against a number of chemotherapy regimens [7,24,40,42].…”

Section: Current and Future Therapeutic Modalitiesmentioning

confidence: 99%

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Hesketh

Batchelor²,

Golant

et al. 2004

Support Care Cancer

125

View full text Add to dashboard Cite

Despite advances in the treatment of many side effects associated with chemotherapy, alopecia remains an issue that is difficult to resolve. Chemotherapy-induced alopecia (CIA) is a condition that can have profound psychosocial and quality-of-life consequences, resulting in anxiety, depression, a negative body image, lowered self-esteem, and a reduced sense of well-being. Patients who fear CIA may sometimes select regimens with less favorable outcomes or may refuse treatment. When supporting patients with CIA, health care providers should use an individualized approach with a focus placed on the actual moment of hair loss. Education, support groups, and self-care strategies are important components of any management approach. No treatment modality for preventing CIA has been clearly shown to be effective. Recent evidence suggests that new scalp hypothermic regimens may be safe and effective. There remains a critical need for effective new approaches to this problem.

show abstract

Section: Current and Future Therapeutic Modalitiesmentioning

confidence: 99%

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Hesketh

Batchelor²,

Golant

et al. 2004

Support Care Cancer

125

View full text Add to dashboard Cite

show abstract

“…Although such treatments were found to be successful in reducing alopecia in connection with certain chemotherapy regimens, they were difficult to standardize and not generally useful over the wide range of pharmacological regimens used in the clinic. Although more recent studies utilizing improved hypothermia devices reported increased reliability, certain antineoplastic drug combinations, notably combinations comprising a taxane could not be protected against (Katsimbri et al 2000;Christodoulou et al 2002). Among the many pharmacological approaches for alopecia prevention that were investigated, vitamin D 3 appeared to be the most promising protective compound because it was effective against several different antineoplastic agents in preclinical experiments (e.g., Jimenez et al 1995;Schilli et al 1998).…”

mentioning

confidence: 99%

Prevention of chemotherapy-induced alopecia in rodent models

Jiménez

Roberts

Mejia

et al. 2008

Cell Stress and Chaperones

View full text Add to dashboard Cite

Alopecia (hair loss) is experienced by thousands of cancer patients every year. Substantial-to-severe alopecia is induced by anthracyclines (e.g., adriamycin), taxanes (e.g., taxol), alkylating compounds (e.g., cyclophosphamide), and the topisomerase inhibitor etoposide, agents that are widely used in the treatment of leukemias and breast, lung, ovarian, and bladder cancers. Currently, no treatment appears to be generally effective in reliably preventing this secondary effect of chemotherapy. We observed in experiments using different rodent models that localized administration of heat or subcutaneous/intradermal injection of geldanamycin or 17-(allylamino)-17-demethoxygeldanamycin induced a stress protein response in hair follicles and effectively prevented alopecia from adriamycin, cyclophosphamide, taxol, and etoposide. Model tumor therapy experiments support the presumption that such localized hair-saving treatment does not negatively affect chemotherapy efficacy.

show abstract

“…There are no approved preventative treatments for CIA in humans although several experimental and pharmacological approaches are under evaluation. Treatments to prevent or minimize alopecia include physical means such as scalp tourniquets (no longer used due to patient discomfort) 20 and scalp hypothermia, 11,21 and pharmacologic means that include topical vitamin D 3 analogue, 22 AS101, 23 Minoxidil [24][25][26] or Cs 27,28 and other experimental drugs. 19 Most of these treatments have either limited or very selective activity or have not been tested in humans yet.…”

Section: Discussionmentioning

confidence: 99%

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Machado

Moreb

Khan

2007

Bone Marrow Transplant

View full text Add to dashboard Cite

Alopecia, a side effect of chemotherapy, is usually temporary and reversible. Irreversible alopecia has been reported after high-dose chemotherapy (HDC) and hematopoietic stem cell transplantation (HSCT) especially related to BuCy containing conditioning regimens; however, the overall incidence is not known. We conducted a retrospective study to identify patients with chemotherapy-induced permanent alopecia after HSCT. We describe six such patients, two males and four females, among 760 patients transplanted between 1997 and 2004. Median age was 45 years (range, 37-65). There were three Caucasians and three African-Americans. Median follow-up was 30 months. Conditioning regimens included BuCy, Bu/Cy and etoposide (VP16) (one of these patients received second autograft after Cy and TBI) and CyVP16 and TBI. Our data show that permanent alopecia is a significant long-term side effect of HSCT and can be seen across the spectrum of diseases and transplant types and with non-busulfan containing regimens. We have observed that patients usually accept permanent alopecia as the price for the cure and therefore true incidence of permanent alopecia may be underestimated. Our findings may also have medico legal and psychosocial implications that need to be taken into consideration when consenting patients for HSCT.

show abstract

Effectiveness of the MSC Cold Cap System in the Prevention of Chemotherapy-Induced Alopecia

Cited by 31 publications

References 5 publications

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches

Prevention of chemotherapy-induced alopecia in rodent models

Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation

Contact Info

Product

Resources

About